Comparative results of treatment for chronic hepatitis C in HIV-infected patients receiving and not receiving highly active antiretroviral therapy

S V Minayeva; G F Moshkovich; M P Goryaeva; L V Varlova; I D Voronina

doi:10.17816/EID40470

Epidemiology and Infectious Diseases ›› 2010, Vol. 15 ›› Issue (3) : 35 -38. DOI: 10.17816/EID40470

Articles

other

Comparative results of treatment for chronic hepatitis C in HIV-infected patients receiving and not receiving highly active antiretroviral therapy

Author information +

History +

PDF

Abstract

The paper presents the comparative results of treatment for chronic hepatitis C in HIV-infected patients in two groups: those who receive and do not receive highly active antiretroviral therapy (HAART). The findings indicated that the efficiency of therapy for hepatitis was comparable in both groups: the proportions of patients with a steady-state virological response who received and did not receive HAART were 34.1 and 40.9%, respectively. Some adverse reactions significantly differed in their frequency in both groups. Nevertheless, their severity was that which did not require hepatitis therapy discontinuance.

Keywords

chronic hepatitis C / HIV infection / highly active antiretroviral therapy

Cite this article

Download citation ▾

S V Minayeva, G F Moshkovich, M P Goryaeva, L V Varlova, I D Voronina. Comparative results of treatment for chronic hepatitis C in HIV-infected patients receiving and not receiving highly active antiretroviral therapy. Epidemiology and Infectious Diseases, 2010, 15(3): 35-38 DOI:10.17816/EID40470

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]

Методические рекомендации Федерального научно-методического центра по профилактике и борьбе со СПИДом Роспотребнадзора "Диспансерное наблюдение, лечение и профилактика вирусных гепатитов у подростков и взрослых, больных ВИЧ-инфекцией" / Кравченко А. В., Ганкина Н. Ю., Канестри В. Г. и др. - М., 2007.

[2]	Кравченко А. В., Ганкина Н. Ю., Канестри В. Г. Особенности антиретровирусной терапии при сочетании ВИЧ-инфекции и хронического вирусного гепатита // Фарматека. - 2008. № 19. - С. 1-8.

[3]	Шахгильдян В. И. Современные подходы к лечению HCV-инфекции у ВИЧ-инфицированных // Гепатол. форум. - 2008. - № 4. - С. 16-27.

[4]	Bannister W. P., Mocroft A. et al. Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients // 9-th International Congress on Drug Therapy in HIV Infection, Glazgow, UK, 9-13 Nov., 2008. - Glazgow, 2008. - P. 13.

[5]	Crum N. F., Riffenburgh R. H., Wegner S. et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early and late HAART eras // J. Acquir. Immune Defic. Syndr. - 2006. - Vol. 41. - P. 194-200.

[6]	Laguno M., Murillas J., Blanco J. L. et al. Peginterferon Alfa-2b plus ribavirin compared with interferon Alfa-2b plus ribavirin for treatment HIV/HCV coinfected patients // AIDS. - 2004. - Vol. 18. - P. F27-F36.

[7]	Mallolas J., Laguno M. Peginterferon Alfa-2b plus ribavirin for treatment naive patients coinfected with HCV and HIV // Expert. Rev. Antiinfect. Ther. - 2008. - Vol. 6. - P. 281-289.

[8]	Moshkovich G., Minaeva S., Tichonova E., Sandova 0. HCV Genotypes distribution in the Nizhny Novgorod area HIV-positive population // 9-th International Congress on Drug Therapy in HIV Infection, Glazgow, UK, 9-13 Nov., 2008. - Glazgow, 2008. - P. 110.

[9]	Soriano V., Barriero P., Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients // J. Antimicrob. Chemother. - 2006. - Vol. 57. - P. 815-818.